as regulators of progression through the cell cycle. Deregulating CDK activity by changes in phosphorylation, cyclin availability or CDK inhibitors all can drive cells prematurely into both S ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Today, attention is turning to understand how non-proliferating cells, cells that have exited the cell cycle, retain their capacity to re-enter when necessary. In the past, this labs study of G1 ...

Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

“We found that pharmacologically targeting a single kinase, CDK2, can trigger two distinct cellular responses depending on the tumor type,” said Vishnu Kumarasamy, PhD, first author on the new study ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Although the benefit/risk of therapeutic inhibition of VSMC proliferation ... is to inhibit cellular proliferation by targeting cell cycle regulation. Here we will review the current understanding ...

My laboratory has combined biochemical, molecular, cellular, and genetic approaches to investigate the roles of CDK inhibitors in differentiation ... for combinatorial therapies with CDK4 inhibitors.

Cyclin-dependent kinase enzymes (CDKs) are of two types: cell cycle-regulating CDKs that participate ... (DRB), a ribonucleic acid polymerase II inhibitor, to analyze the consequences of CDK12 ...

inhibitor in clinical development. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across ...